This cohort study assesses whether PIK3CA mutations among patients with ERBB2/HER2-positive early breast cancer are associated with treatment response and outcome, and if these associations vary by hormone receptor status or intrinsic molecular subtype. This evidence concerns the gene ERBB2 and breast cancer.